Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

A trial to compare efficacy and safety of follitropin delta versus placebo (inactive treatment) in the treatment of men with idiopathic infertility (unexplained reduction of semen quality).

A legfontosabb adatok

Ki végzi
Ferring Pharmaceuticals A/S
Hol
Belgium, Dánia, Németország, Olaszország, Spanyolország és Svédország10 helyszín, 6 országbanVálassz országot a helyszínekhez
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
197 fő vett részt
Kezdés
2023. jan. 12.
Befejezés
2024. okt. 23.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2024. október 16.

Ki vehet részt

Életkor
18 év – 64 év
Nem
Csak férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • History of infertility for 12-60 months with current partner at randomisation
  • Agree to provide information on female partner's positive urine pregnancy test(s) and documentation of ultrasound(s), delivery, and neonatal/infant health
  • Current partner fulfilling the criteria below: a) Pre-menopausal woman between the ages of 18 and 35 years. b) Regular menstrual cycles of 21-35 days. c) No history or current condition of pelvic inflammatory disease, endometriosis stage II-IV by definite or empirical diagnosis, or tubal ligation. d) Agree not to obtain infertility treatment outside of this trial for 9 months from randomisation of male subject
  • Men between the ages of 18 and 50 years
  • Total sperm count 5-39 million at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomisation
  • Total sperm motility of ≥10% at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomisation
  • Semen volume ≥1.4 mL at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomisation
  • Serum follicle-stimulating hormone (FSH) levels of 1.5-8.0 IU/L (measured at central laboratory) at screening
  • Serum luteinising hormone (LH) levels of 1.2-7.5 IU/L (measured at central laboratory) at screening
  • Serum total testosterone levels of ≥300 ng/dL (equals ≥10.4 nmol/L; measured at central laboratory) at screening
  • Agree to have regular intercourse with current female partner with the intent of spontaneous conception within 9 months from randomisation

Ki nem vehet részt

  • Previous FSH treatment not leading to conception
  • Administration of hormonal preparations, agents known to impair testicular function or affect sex hormone secretion, and known or suspected teratogens within 3 months prior to screening. Administration of anabolic steroids within 12 months prior to screening
  • Past or current use of finasteride within 3 months prior to screening
  • Any known uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders)
  • Any history of anatomical disorder of the pituitary gland or testes
  • Any known, clinically significant, systemic disease in addition to the trial indication that might negatively impact fertility
  • Known history of cryptorchidism, testicular torsion, or orchitis
  • Current or past treatment of urogenital (kidney, bladder, testicular, or prostate) cancer as well as history of chemo- or radiotherapy that can have impact on testes
  • Any structural abnormalities of the vas deferens (unilateral or bilateral) at screening
  • Known history or presence of clinical varicocele (subclinical and Grade 1 varicocele are acceptable)
  • Known abnormal karyotype (including Y-chromosome microdeletion)

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

6 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To investigate the effect of FE 999049 treatment of men with idiopathic infertility on the chance of spontaneous pregnancy in their female partners.

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of FE 999049 for treatment of men with idiopathic infertility
A regiszteradat frissítve
2024. október 16.